Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period
Authors:
- Yukihiko HiraiYHYukihiko Hirai
- Masamichi IshizakiMIMasamichi Ishizaki
- Hiroshi TakahashiHTHiroshi Takahashi
- Hideki HanawaHHHideki Hanawa
- Yoshitaka FukunagaYFYoshitaka Fukunaga
- Takashi ShimadaTSTakashi Shimada
- 1 March 2009
- journal article
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 96 (3) , 91-96
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Enzyme replacement therapy with agalsidase alfa in children with Fabry diseaseActa Paediatrica, 2006
- Enzyme-Replacement Therapy With Agalsidase Alfa in Children With Fabry DiseasePediatrics, 2006
- Evasion of Immune Responses to Introduced Human Acid α-Glucosidase by Liver-Restricted Expression in Glycogen Storage Disease Type IIMolecular Therapy, 2005
- Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectorsGene Therapy, 2005
- Impact of Humoral Immune Response on Distribution and Efficacy of Recombinant Adeno-Associated Virus-Derived Acid α-Glucosidase in a Model of Glycogen Storage Disease Type IIHuman Gene Therapy, 2005
- Efficacy of an Adeno-associated Virus 8-Pseudotyped Vector in Glycogen Storage Disease Type IIMolecular Therapy, 2005
- Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria miceGene Therapy, 2004
- Correction of the Nonlinear Dose Response Improves the Viability of Adenoviral Vectors for Gene Therapy of Fabry DiseaseHuman Gene Therapy, 2002
- Correction of Enzymatic and Lysosomal Storage Defects in Fabry Mice by Adenovirus-Mediated Gene TransferHuman Gene Therapy, 1999
- Immunohistochemical characterization of transgenic mice highly expressing human lysosomal α-galactosidaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1998